642 related articles for article (PubMed ID: 25587657)
21. An integrated overview of HIV-1 latency.
Ruelas DS; Greene WC
Cell; 2013 Oct; 155(3):519-29. PubMed ID: 24243012
[TBL] [Abstract][Full Text] [Related]
22. Can HIV infection be eradicated through use of potent antiviral agents?
Josefsson L; Dahl V; Palmer S
Curr Opin Infect Dis; 2010 Dec; 23(6):628-32. PubMed ID: 20847693
[TBL] [Abstract][Full Text] [Related]
23. Depicting HIV-1 Transcriptional Mechanisms: A Summary of What We Know.
Dutilleul A; Rodari A; Van Lint C
Viruses; 2020 Dec; 12(12):. PubMed ID: 33287435
[TBL] [Abstract][Full Text] [Related]
24. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
[TBL] [Abstract][Full Text] [Related]
25. Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals.
Siliciano JD; Siliciano RF
Methods Mol Biol; 2005; 304():3-15. PubMed ID: 16061962
[TBL] [Abstract][Full Text] [Related]
26. Gut and blood differ in constitutive blocks to HIV transcription, suggesting tissue-specific differences in the mechanisms that govern HIV latency.
Telwatte S; Lee S; Somsouk M; Hatano H; Baker C; Kaiser P; Kim P; Chen TH; Milush J; Hunt PW; Deeks SG; Wong JK; Yukl SA
PLoS Pathog; 2018 Nov; 14(11):e1007357. PubMed ID: 30440043
[TBL] [Abstract][Full Text] [Related]
27. The Molecular Biology of HIV Latency.
Khoury G; Darcis G; Lee MY; Bouchat S; Van Driessche B; Purcell DFJ; Van Lint C
Adv Exp Med Biol; 2018; 1075():187-212. PubMed ID: 30030794
[TBL] [Abstract][Full Text] [Related]
28. Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells.
Choudhary SK; Archin NM; Margolis DM
J Infect Dis; 2008 Apr; 197(8):1162-70. PubMed ID: 18419522
[TBL] [Abstract][Full Text] [Related]
29. A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients.
Monie D; Simmons RP; Nettles RE; Kieffer TL; Zhou Y; Zhang H; Karmon S; Ingersoll R; Chadwick K; Zhang H; Margolick JB; Quinn TC; Ray SC; Wind-Rotolo M; Miller M; Persaud D; Siliciano RF
J Virol; 2005 Apr; 79(8):5185-202. PubMed ID: 15795302
[TBL] [Abstract][Full Text] [Related]
30. Therapeutics for HIV-1 reactivation from latency.
Sgarbanti M; Battistini A
Curr Opin Virol; 2013 Aug; 3(4):394-401. PubMed ID: 23810462
[TBL] [Abstract][Full Text] [Related]
31. Recurrent HIV-1 integration at the BACH2 locus in resting CD4+ T cell populations during effective highly active antiretroviral therapy.
Ikeda T; Shibata J; Yoshimura K; Koito A; Matsushita S
J Infect Dis; 2007 Mar; 195(5):716-25. PubMed ID: 17262715
[TBL] [Abstract][Full Text] [Related]
32. Latency reversal and viral clearance to cure HIV-1.
Margolis DM; Garcia JV; Hazuda DJ; Haynes BF
Science; 2016 Jul; 353(6297):aaf6517. PubMed ID: 27463679
[TBL] [Abstract][Full Text] [Related]
33. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
Elliott JH; Wightman F; Solomon A; Ghneim K; Ahlers J; Cameron MJ; Smith MZ; Spelman T; McMahon J; Velayudham P; Brown G; Roney J; Watson J; Prince MH; Hoy JF; Chomont N; Fromentin R; Procopio FA; Zeidan J; Palmer S; Odevall L; Johnstone RW; Martin BP; Sinclair E; Deeks SG; Hazuda DJ; Cameron PU; Sékaly RP; Lewin SR
PLoS Pathog; 2014 Oct; 10(10):e1004473. PubMed ID: 25393648
[TBL] [Abstract][Full Text] [Related]
34. Didehydro-Cortistatin A: a new player in HIV-therapy?
Mousseau G; Valente ST
Expert Rev Anti Infect Ther; 2016; 14(2):145-8. PubMed ID: 26581953
[TBL] [Abstract][Full Text] [Related]
35. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.
Chun TW; Carruth L; Finzi D; Shen X; DiGiuseppe JA; Taylor H; Hermankova M; Chadwick K; Margolick J; Quinn TC; Kuo YH; Brookmeyer R; Zeiger MA; Barditch-Crovo P; Siliciano RF
Nature; 1997 May; 387(6629):183-8. PubMed ID: 9144289
[TBL] [Abstract][Full Text] [Related]
36. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.
Laird GM; Bullen CK; Rosenbloom DI; Martin AR; Hill AL; Durand CM; Siliciano JD; Siliciano RF
J Clin Invest; 2015 May; 125(5):1901-12. PubMed ID: 25822022
[TBL] [Abstract][Full Text] [Related]
37. Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation.
Abdel-Mohsen M; Chavez L; Tandon R; Chew GM; Deng X; Danesh A; Keating S; Lanteri M; Samuels ML; Hoh R; Sacha JB; Norris PJ; Niki T; Shikuma CM; Hirashima M; Deeks SG; Ndhlovu LC; Pillai SK
PLoS Pathog; 2016 Jun; 12(6):e1005677. PubMed ID: 27253379
[TBL] [Abstract][Full Text] [Related]
38. HIV-1 dynamics in vivo: implications for therapy.
Simon V; Ho DD
Nat Rev Microbiol; 2003 Dec; 1(3):181-90. PubMed ID: 15035022
[TBL] [Abstract][Full Text] [Related]
39. Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy.
Persaud D; Ray SC; Kajdas J; Ahonkhai A; Siberry GK; Ferguson K; Ziemniak C; Quinn TC; Casazza JP; Zeichner S; Gange SJ; Watson DC
AIDS Res Hum Retroviruses; 2007 Mar; 23(3):381-90. PubMed ID: 17411371
[TBL] [Abstract][Full Text] [Related]
40. Th1/17 Polarization of CD4 T Cells Supports HIV-1 Persistence during Antiretroviral Therapy.
Sun H; Kim D; Li X; Kiselinova M; Ouyang Z; Vandekerckhove L; Shang H; Rosenberg ES; Yu XG; Lichterfeld M
J Virol; 2015 Nov; 89(22):11284-93. PubMed ID: 26339043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
